6.32
2.10%
0.13
Finanzdaten der Cytek Biosciences Inc-Aktie (CTKB)
Gewinn- und Verlustrechnung
Vierteljährlich
*Alle Zahlen in Millionen
Enddatum des Zeitraums | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 |
Periodenlänge | 3 Monate | 3 Monate | 3 Monate | 3 Monate | 3 Monate |
Revenues |
22.96%
44.86
|
58.23 | 48.00 | 49.69 | 37.09 |
Cost Of Revenue |
13.25%
21.85
|
25.18 | 20.82 | 21.53 | 16.05 |
Gross Profit |
30.36%
23.01
|
33.05 | 27.18 | 28.16 | 21.04 |
Operating Expenses
|
1.69%
33.75
|
33.19 | 33.60 | 37.29 | 33.20 |
Interest Income/Expense |
11.93%
0.441
|
0.394 | 0.595 | 0.409 | 0.673 |
Benefits Costs and Expenses |
0.50%
53.85
|
54.12 | 52.19 | 56.29 | 46.13 |
Costs And Expenses |
0.50%
53.85
|
54.12 | 52.19 | 56.29 | 46.13 |
Operating Income/Loss |
7,735%
-10.73
|
-0.137 | -6.42 | -9.127 | -12.16 |
Nonoperating Income/Loss |
59.02%
1.741
|
4.248 | 2.235 | 2.532 | 3.122 |
Income/Loss From Continuing Operations Before Tax |
318.75%
-8.993
|
4.111 | -4.185 | -6.595 | -9.04 |
Income Tax Expense/Benefit |
102.87%
-2.824
|
-1.392 | 2.271 | -2.207 | -2.233 |
Income/Loss From Continuing Operations After Tax |
212.10%
-6.169
|
5.503 | -6.456 | -4.388 | -6.807 |
Net Income/Loss
|
212.10%
-6.169
|
5.503 | -6.456 | -4.388 | -6.807 |
Preferred Stock Dividends And Other Adjustments |
-
|
- | - | - | - |
Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
Basic Average Shares |
22,678%
130.92
|
-0.5799 | 136.17 | 135.92 | 135.49 |
Diluted Average Shares |
22,678%
130.92
|
-0.5799 | 136.17 | 135.92 | 135.49 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
-
|
- | - | - | - |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):